However, the rate drops to 77% for triple‐negative [estrogen receptor negative (ER−), progesterone receptor negative (PR−), and human epidermal growth factor receptor 2 negative (HER2−)] breast cancer [3], which accounts for 10–15% of the total diagnosed breast cancer [4]. This evidence concerns the gene ERBB2 and breast cancer.